Cargando…

Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy

The North Star ambulatory assessment (NSAA) is a functional motor outcome measure in Duchenne muscular dystrophy (DMD), widely used in clinical trials and natural history studies, as well as in clinical practice. However, little has been reported on the minimal clinically important difference (MCID)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayyar Gupta, Vandana, Pitchforth, Jacqueline M., Domingos, Joana, Ridout, Deborah, Iodice, Mario, Rye, Catherine, Chesshyre, Mary, Wolfe, Amy, Selby, Victoria, Mayhew, Anna, Mazzone, Elena S., Ricotti, Valeria, Hogrel, Jean-Yves, Niks, Erik H., de Groot, Imelda, Servais, Laurent, Straub, Volker, Mercuri, Eugenio, Manzur, Adnan Y., Muntoni, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132589/ https://www.ncbi.nlm.nih.gov/pubmed/37099511 http://dx.doi.org/10.1371/journal.pone.0283669

Ejemplares similares

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
por: Ricotti, Valeria, et al.
Publicado: (2016)

Growth pattern trajectories in boys with Duchenne muscular dystrophy
por: Stimpson, Georgia, et al.
Publicado: (2022)

Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial
por: Muntoni, Francesco, et al.
Publicado: (2022)

Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy
por: Chesshyre, Mary, et al.
Publicado: (2022)

Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy
por: Zambon, Alberto A., et al.
Publicado: (2022)

North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up
por: Coratti, Giorgia, et al.
Publicado: (2021)

DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials
por: Muntoni, Francesco, et al.
Publicado: (2023)

Letter to the Editor: In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2023)

Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2019)

International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15–16 February 2012
por: Mercuri, Eugenio, et al.
Publicado: (2012)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
por: Frank, Diane E., et al.
Publicado: (2020)

Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy
por: Mercuri, Eugenio, et al.
Publicado: (2016)

Non-specific aortoarteritis (NSAA) in children: a prospective observational study
por: Gupta, Himanshu, et al.
Publicado: (2021)

Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy
por: Ricotti, Valeria, et al.
Publicado: (2023)

Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials
por: Ricotti, Valeria, et al.
Publicado: (2016)

Development of a novel startle response task in Duchenne muscular dystrophy
por: Maresh, Kate, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy
por: Ricotti, Valeria, et al.
Publicado: (2016)

Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy
por: Lilien, Charlotte, et al.
Publicado: (2021)

The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
por: Scaglioni, Dominic, et al.
Publicado: (2021)

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
por: Servais, Laurent, et al.
Publicado: (2022)

Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency
por: Maresh, Kate, et al.
Publicado: (2022)

Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy
por: Strandberg, Kristin, et al.
Publicado: (2020)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
por: Signorelli, Mirko, et al.
Publicado: (2019)

Gene therapy in Duchenne muscular dystrophy: Identifying and preparing for the challenges ahead
por: Heslop, Emma, et al.
Publicado: (2021)

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
por: Spitali, Pietro, et al.
Publicado: (2018)

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
por: Mah, Jean K., et al.
Publicado: (2022)

Lessons Learned From Translational Research in Neuromuscular Diseases: Impact on Study Design, Outcome Measures and Managing Expectation
por: Stimpson, Georgia, et al.
Publicado: (2021)

Rimeporide as a ﬁrst- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy
por: Previtali, Stefano C., et al.
Publicado: (2020)

Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53
por: Brogna, Claudia, et al.
Publicado: (2019)

A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment
por: Le Moing, Anne-Gaëlle, et al.
Publicado: (2016)

Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53
por: Brogna, Claudia, et al.
Publicado: (2019)

Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy
por: Wood, C. L., et al.
Publicado: (2019)

Decision-Making And Selection Bias in Four Observational Studies on Duchenne and Becker Muscular Dystrophy
por: Naarding, Karin J., et al.
Publicado: (2020)

Resting-state functional MRI shows altered default-mode network functional connectivity in Duchenne muscular dystrophy patients
por: Doorenweerd, Nathalie, et al.
Publicado: (2021)

Response of plasma microRNAs to nusinersen treatment in patients with SMA
por: Zaharieva, Irina T., et al.
Publicado: (2022)

Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy
por: Zaharieva, Irina T., et al.
Publicado: (2013)

Is ongoing testosterone required after pubertal induction in Duchenne muscular dystrophy?
por: Wood, Claire L, et al.
Publicado: (2023)

Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation
por: Houwen‐van Opstal, Saskia L. S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_smnvq4ie97l4k7sed36q6k0h83